Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its third quarter 2023 financial results and corporate update for Tuesday, November 7, 2023. The schedule for the press release and conference call/webcast are as follows:
- 10/24/2023
|
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
- Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.
- 09/12/2023
|
3 Stocks to Buy For the COVID Resurgence
- The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.
- 09/07/2023
|
Arbutus to Participate in Two Upcoming Investor Conferences
- WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences:
- 09/07/2023
|
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
- Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago.
- 08/03/2023
|
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2023 financial results and corporate update for Thursday, August 3, 2023. The schedule for the press release and conference call/webcast are as follows:
- 07/20/2023
|
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
- WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2023 taking place June 21 - 24, 2023 in Vienna, Austria.
- 06/07/2023
|
Arbutus to Present at Jefferies Healthcare Conference
- WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at the Jefferies Healthcare Conference taking place in New York on Wednesday, June 7, 2023 at 9:30 am ET.
- 05/31/2023
|
Arbutus (ABUS) Upgraded to Buy: Here's Why
- Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/09/2023
|
Arbutus to Present at JMP Securities Life Sciences Conference
- WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference taking place in New York on Tuesday, May 16, 2023 at 9:00 am ET.
- 05/09/2023
|
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
- Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.
- 05/04/2023
|
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
- Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago.
- 05/04/2023
|
Arbutus Biopharma clinical hold slows hepatitis B momentum: broker
- Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that its investigational new drug application for its novel, oral PD-L1 inhibitor AB-101 for hepatitis B has been put on a clinical hold by the US Food and Drug Administration (FDA). The company said AB-101 was designed to “reawaken and boost” the immune system of chronic hepatitis B patients and believes that, when used in combination with other approved therapies, could potentially lead to a functional cure in hepatitis B patients.
- 04/26/2023
|
Why Arbutus Biopharma Stock Is Sinking Today
- The FDA has placed a clinical hold on AB-101, Arbutus' experimental chronic hepatitis B virus therapy. Arbutus had hoped to advance AB-101 into early-stage testing and report initial data on it later this year.
- 04/25/2023
|
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its first quarter 2023 financial results and corporate update for Thursday, May 4, 2023. The schedule for the press release and conference call/webcast are as follows:
- 04/20/2023
|
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
- Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted as late-breaker oral presentations at the Global Hepatitis Summit 2023 taking place April 25-28, 2023, in Paris.
- 04/18/2023
|
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2022 financial results and corporate update for Thursday, March 2, 2023. The schedule for the press release and conference call/webcast are as follows:
- 02/16/2023
|
Arbutus to Participate in Three Upcoming Investor Conferences
- WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following three upcoming investor conferences:
- 02/06/2023
|
Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call Transcript
- Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - President and Chief Executive Officer David Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies Roy Buchanan - JMP Keay Nakae - Chardan Operator Good day. And thank you for standing by, and welcome to Arbutus Biopharma Corporation's 2022 Third Quarter Financial Results and Corporate Update Conference Call.
- 11/09/2022
|
Arbutus to Present at Jefferies London Healthcare Conference
- WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus' President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 11:30 am GMT / 6:30 am EDT.
- 11/08/2022
|
Arbutus to Present at Chardan's 6th Annual Genetic Medicines Conference
- WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET.
- 09/22/2022
|
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2022 Earnings Conference Call August 4, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - President & Chief Executive Officer David Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike Sofia - Chief Scientific Officer Conference Call Participants Roy Buchanan - JMP Securities Dennis Ding - Jefferies Brian Skorney - Baird Keay Nakae - Chardan Thomas Yip - H.C. Wainwright Operator Good morning.
- 08/04/2022
|
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference call/webcast are as follows:
- 07/21/2022
|
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
- Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug for oncology use.
- 06/29/2022
|
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
- JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the Study of the Liver International Liver Congress. The analysts said that.
- 06/28/2022
|
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
- Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.
- 06/08/2022
|
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
- Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET
- 06/08/2022
|
Arbutus to Participate in June Investor Conferences
- WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York:
- 06/02/2022
|
Arbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call Transcript
- Arbutus Biopharma Corp, Inc. (NASDAQ:ABUS ) Q1 2022 Earnings Conference Call May 5, 2022 8:45 AM ET Company Participants Lisa Caperelli - VP, IR William Collier - President, CEO & Director Michael Sofia - Chief Scientific Officer David Hastings - CFO & CAO Gaston Picchio - Chief Development Officer Conference Call Participants Douglas Buchanan - JMP Securities Yuchen Ding - Jefferies Thomas Yip - H.C. Wainwright & Co. Luke Herrmann - Robert W.
- 05/05/2022
|
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
- Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its first quarter 2022 financial results and corporate update for Thursday, May 5, 2022. The schedule for the press release and conference call/webcast are as follows:
- 04/21/2022
|
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
- Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.
- 03/07/2022
|
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
- 03/03/2022
|
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
- Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/03/2022
|
Arbutus, Genevant sue Moderna, citing patent infringement
- Shares of Arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the company said it is suing Moderna Inc. MRNA, +1.70% for infringing on several patents that relate to Moderna's COVID-19 vaccine. Arbutus filed the lawsuit with Genevant Sciences Corp., a privately held company.
- 02/28/2022
|
Arbutus files patent infringement lawsuit against Moderna
- Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.
- 02/28/2022
|
4 Penny Stocks To Buy For Under $5 With Unusual Options Activity
- Penny stocks to buy for under $5 that have unusual options activity right now. The post 4 Penny Stocks To Buy For Under $5 With Unusual Options Activity appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/22/2022
|
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows:
- 02/17/2022
|
Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- 02/12/2022
|
What's the Outlook for Arbutus Biopharma?
- The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.
- 02/05/2022
|
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
- WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022.
- 01/04/2022
|
Roivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy Arbutus
- ROIV has moved up 88% in December in reaction to a patent dispute between Moderna and Arbutus falling in favor of Arbutus. The patent is licensed to a private company called Genevant. ROIV owns an effective 88% stake through direct ownership and its stake in ABUS.
- 12/21/2021
|
Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
- Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus (HBV). In December 2021, ABUS reported its victory in the patent dispute over Moderna, involving its licensed four-lipid nanoparticles delivery system.
- 12/17/2021
|
Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets
- 5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/14/2021
|
Why Arbutus Biopharma Shares Are Rising
- Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President and Chief Executive Officer of Arbutus Biopharma, commented, "Qilu is an ideal partner for our AB-729 RNAi therapeutic given their extensive development, regulatory and commercialization capabilities in China.
- 12/13/2021
|
Got $5 to Spend on Penny Stocks? Check These 4 Out
- Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?
- 12/10/2021
|
4 Penny Stocks That Are Trending on Reddit Right Now and Why
- Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/09/2021
|
5 Penny Stocks To Buy According To Analysts & Targets Up To 341%
- Analysts are bullish on these penny stocks in 2021. Should you be?
- 12/08/2021
|
Arbutus Biopharma (ABUS) Stock: Why The Price Jumped Today
- The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 10% during intraday trading today. This is why it happened.
- 12/07/2021
|
Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact
- Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks. In April 2021, Arbutus, X-Chem Inc, and Proteros biostructures GmbH entered a discovery research and license agreement of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease.
- 12/07/2021
|
Moderna drops, Arbutus pops after patent ruling means vaccine maker could owe royalties on billions in COVID shot revenue
- The patents subject to the court's ruling cover a lipid formulation for nucleic acid delivery, which is essential for Moderna's COVID-19 vaccines.
- 12/01/2021
|
Arbutus Biopharma (ABUS) Stock: Why The Price Is Surging Today
- The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 50% during intraday trading today. This is why it happened.
- 12/01/2021
|
Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
- Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. Arbutus shares are soaring after the Patent Trial and Appeals Board has turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on the COVID-19 Vaccine Delivery Technology Patent.
- 12/01/2021
|
Why Arbutus Shares Are Soaring Today
- Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-delivery technology. A federal appeals court upheld the ruling to not invalidate patents held by Arbutus.
- 12/01/2021
|
Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent
- Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals Board has turned down Moderna, Inc.'s (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-delivery technology used in the former's COVID-19 vaccine.
- 12/01/2021
|
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
- Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon.
- 11/19/2021
|
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
5 Short Squeeze Penny Stocks To Watch For November 2021
- Are these penny stocks ready to short squeeze? The post 5 Short Squeeze Penny Stocks To Watch For November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/26/2021
|
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021. The schedule for the press release and conference call/webcast are as follows:
- 10/21/2021
|
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
- Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?
- 10/10/2021
|
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
- Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/03/2021
|
Arbutus to Participate in October Investor Conferences
- WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences:
- 09/28/2021
|
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
- Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
- 09/27/2021
|
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
- WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced the Company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus' Chief Financial Officer.
- 09/21/2021
|
ABUS Stock: Why It Increased This Week
- The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased more than 12.5% over the past few trading days. This is why it happened.
- 09/10/2021
|
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
- Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
- 08/23/2021
|
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
- Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC™
- 08/05/2021
|
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
- WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 4:05 PM ET.
- 08/03/2021
|
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
- WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter 2021 financial results and corporate update for Thursday, August 5, 2021. The schedule for the press release and conference call/webcast are as follows:
- 07/29/2021
|
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
- Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/08/2021
|
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
- Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatitis B virus infection (CHB)
- 07/07/2021
|
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
- The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:ABUS).
- 07/06/2021
|
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
- Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. The Phase 2a trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus's AB-729, followed by Vaccitech's VTP-300, in NrtI-suppressed subjects.
- 07/06/2021
|
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
- WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus (HBV) infection (CHB) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy.
- 07/06/2021
|
Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
- Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation.
- 06/29/2021
|
ABUS Stock Price Increased Over 15% Pre-Market: Why It Happened
- The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 15% pre-market. This is why it happened.
- 06/28/2021
|
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
- AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks
- 06/26/2021
|
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
- Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021
- 06/02/2021
|
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
- AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data
- 05/05/2021
|
Arbutus Biopharma Stocks Is Trading Higher On Pan-Coronavirus Research Pact
- Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro). The collaboration's goal is to identify safe and effective therapies against coronaviruses, including SARS-CoV-2.
- 04/01/2021
|
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
- Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks
- 04/01/2021
|
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection
- WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has received regulatory approval to initiate a Phase 1a/1b clinical trial with AB-836, its proprietary oral capsid inhibitor for the treatment of HBV infection.
- 03/16/2021
|
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2020 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
- Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/04/2021
|
Recap: Arbutus Biopharma Q4 Earnings
- Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 6.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 50.00% year over year to ($0.23), which missed the estimate of ($0.22).
- 03/04/2021
|
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
- Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/03/2021
|
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection
- Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for chronic HBV infection. The companies announced a clinical collaboration agreement in August last year.
- 02/26/2021
|
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
- Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy
- 02/26/2021
|
Arbutus: A Promising Pure-Play On The $2.13 Billion Global Hepatitis B Market
- Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.
- 01/25/2021
|
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
- 2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs
- 01/25/2021
|
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
- WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 – 14, 2021.
- 01/04/2021
|
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
- Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
- 12/15/2020
|
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
- Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p
- 12/10/2020
|
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
- Data released today expands on November 15, 2020 AASLD presentation
- 11/16/2020
|
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
- Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted
- 11/15/2020
|
Arbutus to Present at Jefferies Virtual London Healthcare Conference
- WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus' President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:35 pm EST (5:35 pm GMT).
- 11/10/2020
|
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
- Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
The Arbutus Biopharma (NASDAQ:ABUS) Share Price Is Up 136% And Shareholders Are Boasting About It
- Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
- 08/17/2020
|
ROCE Insights For Arbutus Biopharma
- Arbutus Biopharma (NASDAQ: ABUS) reported Q2 sales of $1.51 million. Earnings fell to a loss of $13.03 million, resulting in a 0.08% decrease from last quarter. In Q1, Arbutus Biopharma brought in $1.49 million in sales but lost $13.04 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Arbutus Biopharma posted an ROCE of -0.2%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on ABUSROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arbutus Biopharma is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.In Arbutus Biopharma's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Recap Arbutus Biopharma reported Q2 earnings per share at $-0.25/share, which did not meet analyst predictions of $-0.24/share.See more from Benzinga * Recap: Arbutus Biopharma Q2 Earnings * Earnings Scheduled For August 7, 2020 * Stocks That Hit 52-Week Highs On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/12/2020
|
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
- Is (ABUS) Outperforming Other Medical Stocks This Year?
- 08/10/2020
|
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
- Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/07/2020
|
Recap: Arbutus Biopharma Q2 Earnings
- Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 45.65% over the past year to ($0.25), which missed the estimate of ($0.24).Revenue of $1,514,000 up by 116.29% from the same period last year, which missed the estimate of $1,740,000.Looking Ahead Arbutus Biopharma hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Aug 07, 2020View more earnings on ABUSTime: 07:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/knwh3svjPrice Action 52-week high: $9.0252-week low: $0.82Price action over last quarter: Up 184.85%Company Description Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.See more from Benzinga * Earnings Scheduled For August 7, 2020 * Stocks That Hit 52-Week Highs On Friday * 17 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/07/2020
|
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies by the end of 2020Actively screening multiple new molecular entities in recently initiated COVID-19 research programCash runway guidance extended into mid-2022 Conference Call and Webcast Scheduled Today at 8:45 AM ETWARMINSTER, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today reports its second quarter 2020 financial results and provides a corporate update.William Collier, President and Chief Executive Officer of Arbutus, stated, “Despite the challenging conditions resulting from the COVID-19 pandemic, we continue to make steady progress in our Phase 1a/1b clinical trial of AB-729, a subcutaneously delivered RNAi agent, and have recently initiated an additional AB-729 90 mg single-dose cohort in HBV DNA positive subjects. We also intend to initiate two 90 mg multi-dose cohorts in the second half of this year.”Mr. Collier added, “Importantly, in March and May of this year we announced positive preliminary results from this trial, and we look forward to providing additional clinical updates in the second half of 2020. We anticipate these updates will include data from 60 mg multi-dose cohorts with dosing intervals every four and eight weeks and 90 mg single-dose week 12 data in HBV DNA negative and positive subjects. We continue to believe AB-729 is a potent RNAi agent capable of reducing HBsAg plasma levels.”Pipeline UpdateAB-729 * AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes using Arbutus’ novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. AB-729 inhibits viral replication and reduces all HBV antigens, including hepatitis B surface antigen (HBsAg), in preclinical models. Reducing HBsAg is thought to be essential to enable the reawakening of a patient’s immune system so that it can respond to the virus. * Arbutus is currently conducting a single- and multi-dose Phase 1a/1b clinical trial to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB-729 in healthy subjects and in subjects with chronic HBV infection. * Preliminary positive safety data in single-dose cohorts of healthy subjects and safety and efficacy data in the 60 mg and 180 mg single-dose cohorts in subjects with chronic HBV infection were reported in March 2020. Additional follow-on week 12 data for the 60 mg single-dose cohort were reported in May 2020. The data demonstrate the robust activity of AB-729 and, at week 12, the 60 mg single-dose achieved equivalent reductions in HBsAg as the 180 mg single-dose and did so while remaining generally safe and well tolerated with no abnormal transaminase values in any of the six subjects. Mean HBsAg changes from baseline: 60 mg Single-Dose Cohort (N=6)180 mg Single-Dose Cohort (N=4) Day 29 mean log10 IU/mL (Standard Error of the Mean)-0.24 (0.13)-0.8 (0.38) Week 12 (day 84) mean log10 IU/mL (Standard Error of the Mean)-0.99 (0.24)-0.98 (0.22) * Arbutus is dosing two 60 mg multi-dose cohorts of subjects with chronic HBV infection with dosing intervals of every four and eight weeks, respectively. Arbutus is also dosing subjects in a 90 mg single-dose cohort. Results from these cohorts are expected in the second half of 2020. We also intend to initiate two 90 mg multi-dose cohorts in the second half of this year. * Arbutus has also initiated an additional AB-729 90 mg single-dose cohort in HBV DNA positive subjects with results expected in the second half of 2020.AB-836: Oral Capsid Inhibitor * AB-836 is an oral HBV capsid inhibitor. HBV core protein assembles into a capsid structure, which is required for viral replication. The current standard-of-care therapy for HBV, primarily nucleos(t)ide analogues that work by inhibiting the viral polymerase, significantly reduce virus replication, but not completely. Capsid inhibitors inhibit replication by preventing the assembly of functional viral capsids. They also have been shown to inhibit the uncoating step of the viral life cycle thus reducing the formation of new covalently closed circular DNA (cccDNA), the genetic reservoir which the virus uses to replicate itself. * In January 2020, Arbutus selected AB-836 as its next-generation oral capsid inhibitor. AB-836 is from a novel chemical series differentiated from Arbutus’ second generation capsid inhibitor candidate, AB-506, as well as competitor compounds. AB-836 has the potential for increased potency and an enhanced resistance profile as compared to AB-506. Arbutus continues to expect completion of IND-enabling studies by the end of 2020.Early HBV R&D Programs * Arbutus’ drug discovery efforts are focused on follow-on compounds for its current HBV pipeline, including the development of oral RNA-destabilizers that have shown compelling antiviral effects in multiple HBV preclinical models. Arbutus is now focused on advancing next-generation oral RNA-destabilizers with chemical scaffolds distinct from Arbutus’ prior generation HBV RNA destabilizer candidate, AB-452, through lead optimization. Arbutus also has several oral anti-PD-L1 inhibitors in lead optimization that are potentially capable of reawakening the immune response to HBV in infected patients.Research Efforts to Combat COVID-19 and Future Coronavirus Outbreaks * Earlier this year, the Company initiated an internal research program to identify new small molecule antiviral medicines to treat COVID-19 and future coronavirus outbreaks. Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, who was awarded the Lasker-DeBakey Award for his discovery of sofosbuvir, brings extensive antiviral drug discovery experience to this new program. Arbutus has also joined forces with the COVID R&D consortium to further support and expedite efforts to address the COVID-19 pandemic. At this time, Arbutus’ COVID-19 research program will focus on the discovery and development of new molecular entities that address specific viral targets including the nsp12 viral polymerase and the viral protease. These targets are essential viral proteins which Arbutus has experience in targeting. The Company is actively screening multiple new oral molecular entities. The establishment of the COVID-19 effort does not impact Arbutus’ current cash burn guidance for 2020 of $54 to $58 million.Genevant Sciences Ltd. Update On July 23, 2020, the United States Patent and Trademark Office before the Patent Trial and Appeal Board (PTAB) announced their decision in Moderna Therapeutics, Inc.’s challenge of the validity of U.S. Patent 8,058,069 (“the '069 Patent”). In this decision, the PTAB determined no challenged claims were unpatentable. While Arbutus is the patent holder, this patent has been licensed to Genevant. The '069 Patent was included in this license agreement between Genevant and Arbutus. Arbutus is gratified by the recent decision of the PTAB, upholding the validity of one of the patents protecting Arbutus’ LNP technology that Arbutus licensed to Genevant. This decision reinforces Arbutus’ continuing belief in the potential of this technology.Arbutus is entitled to receive tiered low single digit royalties on future sales of Genevant products covered by the licensed patents. If Genevant sub-licenses the intellectual property licensed by Arbutus to Genevant, Arbutus would receive upon the commercialization of a product developed by such sub-licensee the lesser of (i) twenty percent of the revenue received by Genevant for such sublicensing and (ii) tiered low single digit royalties on product sales by the sublicensee.On July 31, 2020, Roivant recapitalized Genevant through an equity investment and conversion of previously issued convertible debt securities held by Roivant. Arbutus participated in the recapitalization of Genevant with an equity investment of $2.5 million. Following the recapitalization, Arbutus owns approximately 16% of the common equity of Genevant. Arbutus’ entitlement to receive future royalties or sublicensing revenue from Genevant remains unchanged.COVID-19 ImpactIn December 2019 an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to nearly every country in the world. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. A number of countries and other jurisdictions around the world have implemented extreme measures to try and slow the spread of the virus. These measures include the closing of businesses and requiring people to stay in their homes, the latter of which raises uncertainty regarding the ability to travel to hospitals in order to participate in clinical trials. Additional measures that have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, include shortages and delays in the supply chain, and prohibitions in certain countries on enrolling subjects in new clinical trials. While we have been able to progress with our clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will negatively impact our plans and timelines in the future.
- 08/07/2020
|
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
- WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 3:30 PM ET. A live webcast of the presentation can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.About ArbutusArbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.Contact Information Investors and MediaWilliam H. Collier President and CEO Phone: 267-469-0914 Email: ir@arbutusbio.com Pam Murphy Investor Relations Consultant Phone: 267-469-0914 Email: ir@arbutusbio.com
- 08/05/2020
|
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
- Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2020
|
1 Reason to Sell Moderna Now
- There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA), one of the drugmakers leading the way to develop a coronavirus vaccine. Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. The biggest impact would be Moderna having to pay royalties to Arbutus on sales of mRNA-1273.
- 07/29/2020
|
Arbutus to Report Second Quarter 2020 Financial Results
- WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020. The schedule for the press release and conference call/webcast are as follows: • Q2 2020 Press Release: August 7, 2020 at 7:30 a.m. ET • Q2 2020 Conference Call/Webcast: August 7, 2020 at 8:45 a.m. ET • Domestic Dial-In Number: (866) 393-1607 • International Dial-In Number: (914) 495-8556 • Conference ID Number: 4974547 A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast.An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4974547.About ArbutusArbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.Contact Information Investors and MediaWilliam H. Collier President and CEO Phone: 267-469-0914 Email: ir@arbutusbio.com Pam Murphy Investor Relations Consultant Phone: 267-469-0914 Email: ir@arbutusbio.com
- 07/29/2020
|
Pfizer/BioNTech COVID-19 Vaccine: A Reality Check
- Pfizer-BioNTech get the go ahead ($1.95 billion contract with the US Government) based on 60 healthy adults receiving first try at formulating the vaccine.
- 07/28/2020
|
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
- Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2020
|
Moderna, Inc.: The Recent Pullback Is No Reason To Accumulate
- With no safety concerns in the Phase 1 trial, Moderna's COVID-19 vaccine candidate is advancing into late-stage studies.
- 07/27/2020
|
Moderna's Patent Snub, And Other News: The Good, Bad And Ugly Of Biopharma
- Moderna has mixed luck with patent snub, but moves ahead with COVID-19 vaccine. Sorrento advances acquisition of SmartPharm.
- 07/27/2020
|
Moderna says patent ruling not to affect COVID-19 vaccine development
- An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine. Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.
- 07/25/2020
|
Moderna Lost a Patent Case and the Stock Is Slipping
- What the decision handed down Thursday by the Patent Trial and Appeal Board could mean for Moderna (ticker: MRNA) isn’t yet clear, but the stock fell 9.5% on Thursday, and was down another 5% Friday in premarket trading. In a statement Friday afternoon, Moderna said that the technology used in its Covid-19 vaccine isn’t covered by the patent its suit had been brought to challenge. Moderna brought the case in January of 2019 against (ABUS) (ABUS), a very small biotech, arguing that its patent for the technology used to deliver messenger RNA to a patients’ cells was unpatentable.
- 07/24/2020
|
Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications
- The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.
- 07/24/2020
|
How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program
- Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session. Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board ruled against Moderna's challenge to the patentability of Arbutus Biopharma Corp's (NASDAQ: ABUS) ABUS'069 patent.The '069 patent covers liquid nanoparticle formulations, or LNPs, meant for nucleic acid delivery, which is used by Moderna in its vaccine candidates.The patent describes the composition of nucleic acid-lipid particles and the ranges in which the different lipid particle components can be combined for effective delivery of nucleic acid sequence payload.Moderna holds four non-exclusive viral vaccine sublicenses of Arbutus-issued LNP delivery technology. Each one allows for the use of pre-April 15, 2010 LNP patent families and is limited to a specific viral target, Chardan analyst Keay Nakae said in a note. These sub-licenses would not be applicable to Moderna's mRNA-1273, the analyst said. Potential Impact On Moderna: The sell-side is in wait-and-watch mode as investors digest the development."This legal dispute has been an ongoing debate among investors, and today's decision is a disappointing turn for MRNA," said SVB Leerink analyst Mani Foroohar said in a note reviewing the development. The analyst initiated coverage of Moderna shares on Thursday. This could lead to a protracted period of investor controversy and debate around the implications of any potential infringement claims by Arbutus regarding Moderna's use of LNP delivery technology in its investigational vaccines, and any further actions Moderna may take to defend its own IP position, the analyst said. Discussions around the ruling will also involve IP and potential royalty/economic claims by Arbutus on Moderna, he said.Foroohar sees any meaningful royalty burden as hampering Moderna's pricing flexibility and margin versus other players in the SARS-CoV-2 vaccine race.This could potentially aggravate downside implications should a HCV-like competitive pricing dynamic emerge, the analyst said. "We continue to watch this emerging dynamic closely, but do not explicitly model any royalty burden, settlement or other financial impact in our MRNA model at this time." MRNA Price Action: At last check, Moderna shares were slipping by 7.22% to $72.13 after plunging about 10% Thursday.Arbutus shares were down 7.9% at $5.71 at last check. Related Links:The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO 5 Coronavirus Stock Valuations Surging During The Pandemic Latest Ratings for MRNA DateFirmActionFromTo Jul 2020SVB LeerinkInitiates Coverage OnMarket Perform Jul 2020JP MorganDowngradesOverweightNeutral Jul 2020Chardan CapitalMaintainsBuy View More Analyst Ratings for MRNA View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs * Novavax Shares Rebound Amid Coronavirus Vaccine Update(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/24/2020
|
Moderna's stock falls the day after 'disappointing' patent ruling
- Shares of Moderna Inc. were down 4.7% in premarket trading on Friday, the day after the U.S. Patent and Trademark Office ruled in favor of Arbutus Biopharma Corp. in a patent dispute between the companies. Shares of Arbutus rallied 15.9% on Friday before the market opened. The decision may mean that Arbutus will attempt to make a royalty claim to products developed by Moderna's lipid nanoparticle delivery technology, which is currently being used to develop a COVID-19 vaccine. SVB Leerink's Mani Foroohar said the ruling is a "disappointing turn" for Moderna, and "any meaningful royalty burden could hamper MRNA's pricing flexibility and margin profile vs other players in the SARS-CoV-2 vaccine market." Moderna is one of a handful of companies that have moved their experimental coronavirus vaccines into clinical trials, and it was the first company to release Phase 1 data about its vaccine candidate. Since the start of the year, Moderna's stock has gained 285.1% and shares of Arbutus are up 123.0%. The S&P 500 is up 0.1% year-to-date.
- 07/24/2020
|
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Acceleron Pharma Inc (NASDAQ: XLRN) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Arbutus Biopharma Corp (NASDAQ: ABUS)( won a patent challenge brought about by Moderna Inc (NASDAQ: MRNA)) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Champions Oncology Inc (NASDAQ: CSBR) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genocea Biosciences Inc (NASDAQ: GNCA) (reacted to its second-quarter results) * Hologic, Inc. (NASDAQ: HOLX) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Medpace Holdings Inc (NASDAQ: MEDP) * NeoGenomics, Inc. (NASDAQ: NEO) * Penumbra Inc (NYSE: PEN) * Quest Diagnostics Inc (NYSE: DGX) * RENALYTIX AI ADR (NASDAQ: RNLX) (IPOed Friday) * ResMed Inc. (NYSE: RMD) * Silk Road Medical Inc (NASDAQ: SILK) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * West Pharmaceutical Services Inc. (NYSE: WST)(reacted to its second quarter results) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 23) * ALX Oncology Holdings Inc (NASDAQ: ALXO) (IPOed last Friday) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Nkarta Inc (NASDAQ: NKTX) * Chanticleer Holdings (NASDAQ: SONN)Related Link: 5 Coronavirus Stock Valuations Surging During The Pandemic Stocks In Focus Radius Health Out-licenses Breast Cancer Drug For Up To $350M Radius Health Inc (NASDAQ: RDUS) said it has entered into an exclusive global license agreement with the Menarini Group for the development and commercialization of elacestrant, an investigational asset that is currently being evaluated in a Phase 3 study as a hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer.Radius will receive an upfront payment of $30 million and up to $320 million in additional payments based on the successful achievement of future development and sales milestones. The company is also eligible for tiered, low to mid-teen percentage royalty payments on global net sales.In pre-market trading Friday, Radius Health shares were rising 9.36% to $13.90.BioMarin Makes Regulatory Submission For Bone Growth Disorder Drug In Europe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the submission of a Marketing Authorization Application to the European Medicines Agency for vosoritide, an investigational, once-daily injection analog of C-type Natriuretic Peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.Subject to completion of EMA's validation check, BioMarin said it anticipates the start of the MAA review to commence in August.Novavax Delays Phase 1 Data Readout, Strikes Coronavirus Manufacturing Deal Novavax, Inc. (NASDAQ: NVAX) said it will release the Phase 1 data, which will consist of preliminary immunogenicity and safety results, during the first week of August, as opposed to the earlier timeframe of July. The Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin shortly thereafter, it added.Novavax also announced an agreement with FUJIFILM Diosynth Biotechnologies, a CDMO, to manufacture bulk drug substance for NVX-CoV2373, the former's COVID-19 vaccine candidate. Fujifilm's site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373, the companies said.View more earnings on IBBThe stock was slipping 4% to $134 in pre-market trading.Arcturus Announces Preliminary Deal to Supply Covid-19 Vaccine Candidate to Israel Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced a binding term sheet with the Israeli Ministry of Health to supply its COVID-19 vaccine candidate, LUNAR-COV19. The parties intend to finalize a comprehensive supply agreement within 30 days, the company said.Earnings LeMaitre Vascular Inc's (NASDAQ: LMAT) second-quarter sales fell a smaller than expected 16% to $24.9 million and EPS fell from 23 cents to 17 cents. The company issued an upbeat guidance for the third quarter.The stock was advancing 12.24% to $32.47 in pre-market trading Friday.Edwards Lifesciences Corp's (NYSE: EW) second-quarter sales fell 15% to $925 million, and adjusted EPS fell 26% to 34 cents. The bottom-line exceeded estimates. The company reiterated its full-year sales guidance of $4 billion to $4.5 billion, and increased its adjusted EPS guidance from $1.58 to $1.75 to $1.75 to $1.95. The sales guidance was in line and the bottom-line guidance exceeded estimates.On The Radar IPOs iTeos Therapeutics, a clinical-stage biopharma engaged in the development of a new generation of highly differentiated immuno-oncology therapeutics for patients, priced its initial public offering, or IPO, of 10.586 million shares at $19.00 per share, above the estimated price range of $16-$18. The shares will begin trading on the Nasdaq under the ticker symbol ITOS. The offering is expected to generate gross proceeds of $201.1 million.Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, priced its IPO of 11 million shares at $19 per share, for generating gross proceeds of $209 million. The company had earlier estimated a price range of $17-$18. The shares will commence trading on the Nasdaq under the ticker symbol NRIX.Inozyme Pharma, Inc, a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, priced its upsized IPO of 7 million shares at $16 per share, for raising gross proceeds of $112 million. The shares are expected to commence trading on the Nasdaq under the ticker symbol INZY.See more from Benzinga * The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results * The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat * The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/24/2020
|
Moderna loses challenge to Arbutus patent on vaccine technology
- An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concepts. LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling could increase pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent portfolio, said Zachary Silbersher, a patent lawyer in New York not involved the case.
- 07/24/2020
|
Moderna Faces Hurdle With Coronavirus Vaccine As Court Refuses To Invalidate Arbutus Patent
- Moderna Inc (NASDAQ: MRNA) has lost the bid to invalidate a key patent related to the development of several of its next-generation vaccines, including one meant for coronavirus, to Arbutus Biopharma Corp (NASDAQ: ABUS), Reuters reported.What Happened The Massachusetts-headquartered company's contention that the '069 patent, related to the technology for delivering mRNA vaccines, owned by Arbutus described obvious concepts was rejected by an administrative court under the United States Patent and Trademark Office on Thursday.The patent is supposedly related to lipid nanoparticle (LNP) technology, which helps the human body create its own therapeutic proteins.A patent lawyer, Zachary Silbersher, told Reuters it was not clear if vaccines developed by Moderna, including the one for COVID-19, infringed upon the Arbutus patent, but efforts by Moderna to invalidate the '069 patent indicate that the biotechnology company sees it as an obstacle."At the end of the day, Arbutus might be able to claim a royalty in the [COVID-19] vaccine," Silbersher said.Why It Matters SVB Leerink analysts said Moderna is unlikely to see any immediate financial impact from the patent ruling.The pharmaceutical company can appeal the court's decision in the U.S. Court of Appeals for the Federal Circuit, however, chance of a success is limited. Several companies have reported positive developments on the COVID-19 vaccine, the latest being AstraZeneca plc (NYSE: AZN), which is working with Oxford University. Last week, Johnson & Johnson (NYSE: JNJ) said it was beginning late-stage human trials for its coronavirus vaccine, while two vaccine candidates from Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) are also under fast-track development.Price Action The court's decision caused Moderna shares to drop nearly 10% to $75.33 and Arbutus's to surge by almost 120% to $6.20 on Thursday's closing.In the after-hours session, Moderna shares slipped by a further 3% to $73.09 while Arbutus shares gained 18.9% to $7.37.See more from Benzinga * Trump Administration Expects Coronavirus Vaccine Production To Start By The End Of Summer(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/24/2020
|
Moderna Dives On Patent Battle That Could Jeopardize Coronavirus Vaccine
- Moderna stock tumbled late Thursday after the biotech lost a patent battle that could jeopardize the financial future of its coronavirus vaccine. Moderna denies a threat to vaccine profits.
- 07/23/2020
|
How R&D Expenses Can Help You Pick Outperforming Stocks
- A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet
- 07/02/2020
|
Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy?
- In this article we will take a look at whether hedge funds think Arbutus Biopharma Corp (NASDAQ:ABUS) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
- 06/16/2020
|
Arbutus to Present at Jefferies Virtual Healthcare Conference
- WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
- 05/27/2020
|
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
- The biotech sector remains in focus with pipeline updates on coronavirus treatments.
- 05/20/2020
|
P/E Ratio Insights for Arbutus Biopharma
- In the current session, Arbutus Biopharma Inc. (NASDAQ: ABUS) is trading at $2.43, after a 29.79% increase. Over the past month, the stock increased by 103.10%, and in the past year, by 16.12%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 33.69%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 7.28 in the biotechnology industry, Arbutus Biopharma has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 15 Healthcare Stocks Moving In Monday's Pre-Market Session * Arbutus Biopharma: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/19/2020
|
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
- Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound. At week 12, the 60 mg single-dose achieved equivalent reductions in HBsAg as the 180 mg single-dose.
- 05/18/2020
|
Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically
- Celebrations may be in order for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with the analysts...
- 05/18/2020
|
Why Arbutus (ABUS) Stock Might be a Great Pick
- Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/15/2020
|
Arbutus' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.
- 05/15/2020
|
3 “Strong Buy” Penny Stocks With Triple-Digit Upside
- Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that the S&P; 500 will hit 3,435 within a year. From current levels, this would reflect a double-digit gain, and come in above the 3,393 high-point posted on February 19. Back in March, he even went so far as to call for a new high in the third quarter, but since then he has updated his forecasts.“We’ve had a lot of people compare it with the Crash of ’29, the Depression of the 1930s, etc. But back then, you had the government actually tightening their reins, balancing their budget — you did not have a reactive Federal Reserve,” Stovall stated. He added, “Who’s to say we don’t go for a retest first? That’s a normal situation. However, I don’t think we’re going to get an even lower low because of the stimulus already injected into the system.”To this end, risk-tolerant investors are looking to take advantage of lower share prices, which present more attractive entry points. What’s the advantage of stocks with bargain price tags, specifically those trading for less than $5 per share? Should these names, which are deemed “penny stocks," experience even minor share price appreciation, it can translate to massive percentage gains.Therefore, huge returns are on the table, but penny stocks aren’t everyone’s cup of tea. Some argue that there could be a good reason they are trading at such low levels, and that the risk outweighs the potential rewards. Understanding the risk involved, we wanted to see if we could track down any compelling penny stocks in the healthcare space. Using TipRanks’ database, we pinpointed three that have received enough support from Wall Street analysts to earn a “Strong Buy” consensus rating. The cherry on top? All three of the tickers could double in the next year. Let’s dive in.Marinus Pharmaceuticals, Inc. (MRNS)Focused on the development of neuropsychiatric therapeutics, Marinus is one of the top players in the orphan epileptic disorder space. Following a first quarter update on the company’s progress, Wall Street believes its long-term growth narrative is strong and that its $2.06 share price reflects the ideal entry point.As part of the update, management announced that the design and dosing for the RSE pivotal Phase 3 trial for its lead development candidate, ganaxolone (GNX), had been confirmed, with it set to begin in the third quarter. The co-primary endpoints for the trial are status cessation within 30 minutes and suppression for at least 24 hours, and it will be powered 90% to hopefully show 30% efficacy for GNX when compared to the placebo. Commenting for Oppenheimer, analyst Jay Olson said, “We view pivotal Phase 3 design as similar to positive Phase 2 trial while benefiting from longer dosing with 12 hours exposure vs. 8 hours prior. MRNS expects top-line data in the first half of 2022.”Additionally, the company finished enrolling participants for its CDD pivotal Phase 3 MARIGOLD trial, with the top-line data also slated for release in the third quarter. Olson argues that the discontinuation rate of less than 10% and high enrollment rate imply that tolerability levels are “favorable." The analyst added, “Pre-commercialization and NDA filing preparations remain on track despite COVID-19. We believe MRNS could have a substantial competitive advantage as a first mover.”If that wasn’t enough, Olson thinks the TSC Phase 2 open-label trial, which should start screening patients in Q2 and could see top-line data published in Q1 2021, could serve as a significant catalyst for shares. While COVID-19's impact on enrollment caused management to downsize the PRE Phase 3 VIOLET trial into a Phase 2 proof-of-concept trial in order to reprioritize resources, MRNS still has plenty going for it.“We view MRNS as well-positioned despite potential COVID-19 disruptions, with $77.8 million cash balance providing runway into 3Q21. We view MRNS's pipeline as attractive with multiple opportunities and several key near-term catalysts. We believe the current share price provides an attractive entry point,” Olson explained.To this end, Olson kept his Outperform call and $6 price target as is. Should this target be met, a twelve-month gain of 191% could be in store. (To watch Olson’s track record, click here) What does the rest of the Street think about Marinus’ long-term growth prospects? It turns out that other analysts also have high hopes. Only Buy ratings have been received in the last three months, so the consensus rating is a Strong Buy. In addition, the $5.50 average price target suggests 168% upside potential. (See Marinus stock analysis on TipRanks)Arbutus Biopharma Corporation (ABUS)With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. Currently going for $1.65 apiece, several members of the Street think now is the time to get on board as multiple catalysts are fast-approaching.On May 11, the company revealed that it plans to share further results from the week 12 portion of the 60 mg single-dose cohort evaluating its lead candidate, a GalNAc delivered RNAi compound, AB-729, in the second quarter of 2020.Five-star analyst Mayank Mamtani, of B.Riley FBR, points out that preliminary data from the Phase 1a/1b AB-729 HBV study showed an HBsAg reduction comparable to advanced RNAi peers, even though it enrolled difficult to treat e-antigen negative patients. As HBsAg reduction rose during the study, the analyst argues that this increases the chances of successful follow-up data.On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. This goes hand in hand with the company’s research efforts to develop an oral HBV RNA-destabilizer and an oral anti-PD-L1 inhibitor. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. Mamtani thinks this approach is promising as Gilead’s experimental COVID-19 treatment, remdesivir, is a nucleotide analog that binds nsp12, which inhibits viral proliferation and produces clinical benefits.Mamtani added, “Nsp12 has also been implicated in HCV, HIV, and, notably, HBV, areas in which ABUS has extensive antiviral development expertise. In concert with the biotech and pharma COVID-19 consortium, ABUS anticipates pooling resources along with leveraging primary screening and lead optimization capabilities to advance novel candidates against known and unknown targets, which works ideally as a pan coronavirus agent in order to also prepare for future outbreaks.”Based on all of the above, it’s no wonder Mamtani reiterated his bullish call. Given the $6 price target, shares could soar 253% in the next twelve months. (To watch Mamtani’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: ABUS is a Strong Buy. The $5 average price target brings the upside potential to 198.5%. (See Arbutus Biopharma stock analysis on TipRanks)Geron Corporation (GERN)Last but not least we have Geron, which is primarily focused on the development of imetelstat, a small molecule telomerase inhibitor active in the treatment of highly transfusion-dependent MDS and r/r myelofibrosis (MF). While it’s very likely that the company will experience some delays as a result of COVID-19, the Street cites its promising technology and bargain $1.36 share price as making it a compelling healthcare play.Some investors have expressed concern regarding GERN’s announcement that it won’t be able to complete enrollment for the Phase 3 IMerge trial by 2020 due to the impact of COVID-19. BTIG analyst Thomas Shrader acknowledges that the delay will push back imetelstat’s approval and launch, which he now thinks will come in 2024 instead of 2023. However, he argued, “Geron’s patients are as desperate as they come in r/r MDS and AML and we expect data to date leave physicians and patients highly motivated to find something to try.”Further explaining the MDS opportunity, Shrader believes the program demonstrates robust levels of durability. Not only does the five-star analyst call the 24-week RBC-TI rate “highly compelling”, but he also highlights the strong safety profile.Shrader said, “Greater than 90% of patients with neutropenias and thrombocytopenias had these AEs resolve prior to the next dose. This reversibility is in contrast to both HMAs and Revlimid where these toxicities result in drug interruptions. A KOL recently commented that the high 68% HI-E response suggests most patients receive some benefit – making any subsequent trials very easy to enroll.”It should be noted that previously, its IMbark trial had a 32% discontinuation rate thanks to lack of efficacy, but Shrader thinks “these discontinuations may have been premature due to the drug’s slow onset of action and its ‘black box nature’ during the trial.” He added, “Based on increased understanding of how imetelstat works and its promise as a therapeutic, this discontinuation rate is likely to be low in subsequent trials.
- 05/14/2020
|
Arbutus to Present at UBS Virtual Global Healthcare Conference
- WARMINSTER, Pa., May 12, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
- 05/12/2020
|
Moving Average Crossover Alert: Arbutus Biopharma
- Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 05/11/2020
|
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
- Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Arbutus Biopharma: Q1 Earnings Insights
- Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 46.81% year over year to ($0.25), which beat the estimate of ($0.39).Revenue of $1,491,000 rose by 113.00% year over year, which beat the estimate of $220,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 11, 2020View more earnings on ABUSTime: 07:05 PM ETWebcast URL: https://edge.media-server.com/mmc/p/r2c9xashPrice Action Company's 52-week high was at $3.66Company's 52-week low was at $0.82Price action over last quarter: down 53.20%Company Overview Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.See more from Benzinga * Stocks That Hit 52-Week Lows On Friday * P/E Ratio Insights for Riot Blockchain * Stocks That Hit 52-Week Highs On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/11/2020
|
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
- Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11,.
- 05/11/2020
|
Arbutus to Report First Quarter 2020 Financial Results
- WARMINSTER, Pa., May 04, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
- 05/04/2020
|
The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts
- One thing we could say about the analysts on Arbutus Biopharma Corporation (NASDAQ:ABUS) - they aren't optimistic...
- 03/31/2020
|
ABT, DD among premarket gainers
- Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric oxid
- 03/30/2020
|
CCL, RBS among premarket losers
- Arlington Asset Investment (NYSE:AI) -21% after suspending Q1 dividend.BGC Partners (NASDAQ:BGCP) -20% on dividend cut.Altimmune (NASDAQ:ALT) -15% on FY earnings.Arbutus Biopharma (NASDAQ:ABUS) -10% d
- 03/27/2020
|
B.Riley FBR Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
- B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $6.00. The company's shares closed
- 03/27/2020
|
B.Riley FBR Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
- B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a
- 03/27/2020
|
The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
- Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 26) * Aptevo Therapeutics Inc (NASDAQ: APVO) (reacted to its fourth-quarter
- 03/27/2020
|
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
- Arbutus Biopharma Corporation (ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced positive preliminary results from a Phase 1a/1b clinical trial (AB-729-001) in healthy subjects and two cohorts of chronic hepatitis B subjects on nucleos(t)ide antiviral therapy, all of whom received a single subcutaneous injection of AB-729. AB-729-001 is an ongoing Phase 1a/1b clinical trial designed to determine the most effective dose and dosing interval for use in future Phase 2 combination clinical trials.
- 03/26/2020
|
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics
- After years of research, technology for silencing a gene---stopping it from producing a disease-causing protein---has reached patients. AstraZeneca is now
- 03/25/2020
|
Arbutus Biopharma (ABUS) Receives a Buy from B.Riley FBR
- B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma (ABUS) on March 13 and set a price target of $6.00. The company's shares
- 03/16/2020
|
Arbutus Biopharma (ABUS) Receives a Buy from B.Riley FBR
- B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) on March 13 and
- 03/16/2020
|
Goldman likes GW Pharma in premarket analyst action
- ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup.Alector (NASDAQ:ALEC) initiated with Buy rating and $40 (36% upside) price target at Citi.
- 03/06/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS
- 03/05/2020
|
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
- Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV).
- 03/05/2020
|
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
- Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for ...
- 02/29/2020
|
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
- WARMINSTER, Pa., Feb. 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
- 02/27/2020
|
Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 - ResearchAndMarkets.com
- The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
- 02/25/2020
|
PLUG, Z among premarket gainers
- Brickell Biotech (NASDAQ:BBI) +64% on positive sofpironium bromide data.Adesto Technologies (NASDAQ:IOTS) +55% on being acquired by Dialog Semiconductor.Stamps.com (NASDAQ:STMP) +39% on Q4 results.E*T
- 02/20/2020
|
Investment Analysts' New Coverage for February, 19th (ABUS, AEE, AEP, CNP, D, ES, ETR, EXC, ITCI, NEE)
- Investment Analysts’ new coverage for Wednesday, February 19th: Robert W. Baird initiated coverage on shares of Arbutus Biopharma (NASDAQ:ABUS). The firm issued an outperform rating on the stock. BMO Capital Markets initiated coverage on shares of Ameren (NYSE:AEE). They issued an outperform rating on the stock. BMO Capital Markets started coverage on shares of American […]
- 02/19/2020
|
Stock Charts To Watch - Wednesday, February 5
- Puma Biotechnology, Inc. exploded Wednesday, jumping 3.98 or 38%, to 14.56, after reaching a high of 15.00, on a whopping 23 million shares traded.
- 02/06/2020
|
6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session
- Gainers
• Moleculin Biotech, Inc. (NASDAQ:MBRX) stock rose 35.2% to $1.19 during Wednesday's pre-market session.
• Arbutus Biopharma, Inc. (NASDAQ:ABUS) shares rose...
- 02/05/2020
|
Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) Head-To-Head Contrast
- Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability. Analyst Ratings This is a summary of recent ratings for Arbutus Biopharma and GlycoMimetics, as reported […]
- 01/17/2020
|
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
- 10/10/2019
|
